期刊文献+

RNA干扰技术抑制Her2基因表达对卵巢上皮性癌细胞生物学特性的影响 被引量:2

Effect of reduced expression of Her2 by RNA interference on the biological characters of ovarian carcinoma cells
原文传递
导出
摘要 目的应用RNA干扰技术,观察稳定转染Her2基因的短发夹状RNA(shRNA)对不同恶性程度的卵巢上皮性癌(卵巢癌)SKOV3和SKOV3.ip1细胞Her2基因表达及细胞生物学特性的影响。方法将表达Her2的质粒pHer2shRNA分别转染SKOV3和SKOV3.ip1细胞,经抗性筛选获得稳定转染的细胞系。RT-PCR技术、蛋白印迹法检测转染前后细胞Her2mRNA和蛋白的表达,体外侵袭实验观察转染前后细胞侵袭能力的改变,裸鼠接种肿瘤细胞观察转染前后细胞成瘤能力的改变。结果转染前后SKOV3.ip1、SKOV3细胞的Her2mRNA表达量分别为(99.9±1.3)%和(42.4±2.5)%、(68.0±3.1)%和(40.8±2.0)%,Her2蛋白的表达量分别为(98.2±1.7)%和(40.7±2.1)%、(72.1±3.4)%和(36.4±1.5)%,稳定转染后,两种细胞的Her2基因表达均明显下降,分别比较,差异均有统计学意义(P〈0.05)。稳定转染pHer2shRNA后,SKOV3.ip1细胞的穿膜细胞数由(36.2±9.7)个下降为(15.7±7.2)个,SKOV3的穿膜细胞数由(7.6±1.1)个下降为(1.8±0.8)个,细胞侵袭能力均显著下降,分别比较,差异均有统计学意义(P〈0.05)。稳定转染pHer2shRNA后,SKOV3.ip1和SKOV3细胞的成瘤重量分别由(1.55±0.31)g下降为(0.69±0.20)g、(1.14±0.10)g下降为(0.38±0.03)g,两种细胞的成瘤能力均显著下降,分别比较,差异均有统计学意义(P〈0.05)。结论(1)针对Her2基因的RNA干扰技术可以显著降低卵巢癌细胞Her2基因的表达水平。(2)经RNA干扰作用降低Her2基因表达后,卵巢癌细胞的生物学特性改变,恶性度降低。 Objective To observe the effects of short hairpin RNA (shRNA) targeting Her2 on its gene expression when the shRNA was stably transfected into human ovarian cell lines, SKOV3 and SKOV3. ipl, which have different extent of malignancy and investigate the changes of the biological characters of the two cell lines after the stable transfection. Methods The plasmids expressing shRNA targeting Her2 gene were transfected into SKOV3 and SKOV3. ipl cells. The stably transfected cells were gained by antibiotic screening. The expression of Her2 before and after the transfection was detected by RTPCR and western blot. The transwell experiment was used to observe the invasion ability of the cancer cells before and after the transfection, and the parent and the transfected cells were injected into nude mice to observe the tumor growth. Results After the stable transfection with Her2 shRNA, mRNA and protein levels of Her2 gene in SKOV3 and SKOV3. ipl cells were remarkably reduced. The expression of mRNA were (68. 0 ± 3. 1 ) %, (40. 8 ± 2.0) %, (99. 9 ± 1.3 ) %, (42.4 ± 2. 5 ) %. The expression of protein were (72. 1 ± 3.4) %, ( 36. 4 ± 1.5 ) %, ( 98.2 ± 1.7 ) %, (40. 7 ± 2. 1 ) %. The invasion ability into basilar membrane of the transfected cells was greatly reduced compared with the parent cells. The invasion cell numbers were 7. 6 ± 1.1, 1.8 ± 0. 8, 36.2 ± 9. 7, 15.7 ± 7.2. The growth rate of the planted tumors was lower in transfected groups than that of the parent groups. Conclusions ( 1 ) The expression of Her2 gene in SKOV3 and SKOV3. ipl cells was remarkably reduced by RNA interference targeting Her2. (2) The biological characters of SKOV3 and SKOV3. ipl cells are changed when the expression of Her2 gene is reduced by RNA interference.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2008年第8期622-625,共4页 Chinese Journal of Obstetrics and Gynecology
基金 北京市自然科学基金(7082098)
关键词 RNA干扰 卵巢肿瘤 基因 ERBB-2 RNA interference Ovarian neoplasms Genes, erbB-2
  • 相关文献

参考文献9

  • 1王克芳,冯捷,昌晓红,程洪艳,成夜霞,郭慧方,付天云,崔恒.RNA干扰技术抑制卵巢癌细胞系SKOV3.ip1细胞内Her-2/neu基因表达的研究[J].中国妇产科临床杂志,2006,7(3):199-202. 被引量:2
  • 2Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem, 1999,45 (8 Pt 1 ) : 1148-1156.
  • 3Hung MC, Lau YK. Basic science of HER2/neu: a review. Semin Oncol, 1999, 26(4 Suppl 12) :51-59.
  • 4Hellstrom I, Goodman G, Pullman J, et al. Overexpression of HER-2 in ovarian carcinomas. Cancer Res, 2001,61:2420-2423.
  • 5Bookman MA, Darey KM, Clarke-pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase Ⅱ trial of the Gynecologic Oncology Group. J Clin Oncol, 2003,21:283-290.
  • 6Kauraniemi P, Kallioniemi A. Activation of multiple cancerassociated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer, 2006,13:39-49.
  • 7张艳红,吴晴.RNAi逆转肿瘤多药耐药的研究进展[J].中国癌症杂志,2007,17(2):160-164. 被引量:2
  • 8Yu D, Wolf JK, Scanlon M, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res, 1993,53:891-898.
  • 9Bai F, Feng J, Cheng Y, et al. Analysis of gene expression patterns of ovarian cancer cell lines with different metastatic potentials. Int J Gynecol Cancer, 2006, 16:202-209.

二级参考文献34

  • 1[1]Fire A,Xu SQ,Montgomery MK,et al.Potent and specific genetic interference by double-stranded RNA in C.elegans.Nature,1998,391 (6669):806-811.
  • 2[2]Sharp PA.RNA interference-2001.Genes Dev,2001,15:485 -490.
  • 3[3]Sui G,Soohoo C,Affarel B,et al.A DNA vector-based RNAi teclmology to suppress gene express in mammalian cells.Proc Natl Acad Sci USA,2002,99:5515-5520
  • 4[4]Bièche I,Onody P,Laurendeau I,et al.Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.Clinical Chemistry,1999,45:1148-1156.
  • 5[5]Lupu R,Cardillo M,Harris L,et al.Interaction between erbB-receptons and heregulin in breast cancer tumor progression and drug resistence.Semin Cancer Biol,1995,6:135-145.
  • 6[6]Ullrich A,Schlessinger J.Signal transduction by receptors with tyrosine kinase activity.Cell,1990,61:203-212.
  • 7[7]Hung MC,Lau YK.Basic sience of HER-2/neu:a review.Semin Oncol,1999,26:51-59.
  • 8[8]Hellstrom I,Goodman G,Pullman J,et al.Overexpression of HER-2in ovarian carcinomas.Cancer Res 2001,61:2420-2423.
  • 9[9]Hogdall EV,Christensen L,Kjaer SK,et al.Distribution of HER-2overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma:from the Danish MALOVA Ovarian Cancer Study.Cancer,2003,98:66-73.
  • 10[10]Bookman MA,Darcy KM,Clarke-pearson D,et al.Evaluation of monoclonal humanized anti-HER2 antibody,trastuzumab,in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:a phase Ⅱ trial of the Gynecologic Oncology Group.J Clin Oncol,2003,21:283-290.

共引文献2

同被引文献3

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部